TABLE 2.
Clinical trials for immune‐related diseases using MSC‐derived products
| Condition | NCT number | Title | Status | Delivery | Auto/allo? | Source MSCs | Age | Phase | First posted |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | NCT02192736 | Safety and Feasibility Study of Intranasal Mesenchymal Trophic Factor (MTF) for Treatment of Asthma | Active, not recruiting | Intranasal | Allo | WJUCMSC‐TFs | 21 to 60 years | Phase 1|Phase 2 | July 17, 2014 |
| ARDS | NCT04544215 | A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection | Recruiting | Aerosol Inhalation | Allo | AdMSC‐Exo | 18 to 75 years | Phase 1|Phase 2 | September 10, 2020 |
| ARDS | NCT04602104 | A Clinical Study of Mesenchymal Stem Cell Exosomes Nebulizer for the Treatment of ARDS | Not yet recruiting | Aerosol Inhalation | Allo | UNS‐MSC‐Exo | 18 to 70 years | Phase 1|Phase 2 | October 26, 2020 |
| COVID‐19 | NCT04276987 | A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia | Completed | Aerosol Inhalation | Allo | AdMSC‐Exo | 18 to 75 years | Phase 1 | February 19, 2020 |
| COVID‐19 | NCT04366063 | Mesenchymal Stem Cell Therapy for SARS‐CoV‐2‐related Acute Respiratory Distress Syndrome | Recruiting | IV | UNS | UNS‐MSCs/MSC‐EVs | 18 to 65 years | Phase 2|Phase 3 | April 28, 2020 |
| COVID‐19 | NCT04398303 | ACT‐20 in Patients With Severe COVID‐19 Pneumonia | Not yet recruiting | IV | Allo | WJUCMSCs/MSC‐CM | 18 to 85 years | Phase 1|Phase 2 | May 21, 2020 |
| COVID‐19 | NCT04657458 | Expanded Access Protocol on Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Infusion Treatment for Patients With COVID‐19 Associated ARDS | Available | IV | UNS | BMMSC‐Evs | 18 years and older | Not Applicable | December 8, 2020 |
| COVID‐19 | NCT04753476 | Treatment of Severe COVID‐19 Patients Using Secretome of Hypoxia‐Mesenchymal Stem Cells in Indonesia | Recruiting | IM | UNS | UNS‐MSC‐secretome | Child, Adult, Older Adult | Phase 2 | February 15, 2021 |
| COVID‐19 | NCT04798716 | The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID‐19 | Not yet recruiting | IV | UNS | UNS‐MSC‐Exo | 18 years and older | Phase 1|Phase 2 | March 15, 2021 |
| Lung injury test in HD | NCT04313647 | A Tolerance Clinical Study on Aerosol Inhalation of Mesenchymal Stem Cells Exosomes In Healthy Volunteers | Recruiting | Aerosol Inhalation | Allo | AdMSC‐Exo | 18 to 45 years | Phase 1 | March 18, 2020 |
| OA | NCT04314661 | Comparative Effectiveness of Arthroscopy and Non‐Arthroscopy Using Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium for Osteoartrithis | Recruiting | Intraarticular | Allo | WJUCMSCs/MSC‐CM | 55 to 70 years | Phase 1|Phase 2 | March 19, 2020 |
| OA | NCT04223622 | Effects of ASC Secretome on Human Osteochondral Explants | Not yet recruiting | Unspecified | UNS | AdMSC‐secretome | 18 years and older | Not Applicable | January 10, 2020 |
| GVHD with dry eye | NCT04213248 | Effect of UMSCs Derived Exosomes on Dry Eye in Patients With cGVHD | Recruiting | On eye | Allo | WJUCMSC‐Exo | 18 to 70 years | Phase 1|Phase 2 | December 30, 2019 |
| T1DM | NCT02138331 | Effect of Microvesicles and Exosomes Therapy on β‐cell Mass in Type I Diabetes Mellitus (T1DM) | Unknown status | IV | Allo | UCBMSC‐Exo | 18 to 60 years | Phase 2|Phase 3 | May 14, 2014 |
| MS | NCT03799718 | Safety and Efficacy of Repeated Administration of NurOwn (MSC‐NTF Cells) in Participants With Progressive MS | Recruiting | Intrathecal | Auto | BMMSC‐NFs | 18 to 65 years | Phase 2 | January 10, 2019 |
| Skin transplant | NCT04234750 | Mesenchymal Stem Cell‐derived Pleiotropic Factor in the Treatment of Donor Sites | Recruiting | On skin | UNS | UNS‐MSC‐CM | 6 to 60 years | Phase 1 | January 21, 2020 |
Abbreviations: Ad, adipose; allo, allogenic; Auto, autologous; IV, intravenous; TF, trophic factor; UCB, umbilical cord blood; UNS, unspecified; WJUC, Wharton's jelly/umbilical cord.